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Introduction {#ijc32233-sec-0001}
============

Prostate cancer is the most frequently diagnosed cancer in men in Europe,[1](#ijc32233-bib-0001){ref-type="ref"} but the well‐established risk factors age, ethnicity, genetic factors and family history of the disease are not modifiable.[2](#ijc32233-bib-0002){ref-type="ref"}, [3](#ijc32233-bib-0003){ref-type="ref"} There is also evidence that circulating insulin‐like growth factor‐I (IGF‐I) is related to higher overall prostate cancer risk,[4](#ijc32233-bib-0004){ref-type="ref"} and obesity has been associated with a higher risk of aggressive disease.[5](#ijc32233-bib-0005){ref-type="ref"} Moreover, the wide international variation in prostate cancer incidence and the changing rates observed in migrant studies suggest that environmental and lifestyle factors, such as dietary factors, are possible risk factors for the disease.[6](#ijc32233-bib-0006){ref-type="ref"} However, some of this international variation is due to differences between countries in prostate‐specific antigen (PSA) testing, which has especially increased the diagnosis of nonaggressive tumors[1](#ijc32233-bib-0001){ref-type="ref"}; therefore, to provide more clarity on prostate cancer etiology, it is important that analytical studies characterize prostate cancer by stage, grade and fatality of the disease.

The possible role of total and specific types of dietary fats in relation to prostate cancer development and progression has attracted much interest.[7](#ijc32233-bib-0007){ref-type="ref"}, [8](#ijc32233-bib-0008){ref-type="ref"} The latest meta‐analysis from the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) stated that the evidence was limited and no conclusion could be reached on whether consumption of total fat, saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs), or polyunsaturated fatty acids (PUFAs) is associated with overall prostate cancer risk or with risk for 'advanced/high grade' prostate cancer.[2](#ijc32233-bib-0002){ref-type="ref"}, [9](#ijc32233-bib-0009){ref-type="ref"} However, this meta‐analysis did not differentiate between stage and grade of the disease because of the small number of available studies with data on both these outcomes, and associations with prostate cancer death were not available. Moreover, recent studies have shown that individual fatty acids may confer heterogeneous health effects,[10](#ijc32233-bib-0010){ref-type="ref"}, [11](#ijc32233-bib-0011){ref-type="ref"}, [12](#ijc32233-bib-0012){ref-type="ref"} which might explain the current inconclusive results on the role of dietary fat on prostate cancer.

The aim of this study was to examine the association of intakes of individual dietary fatty acids with the risk of prostate cancer, and to examine whether any associations differ by tumor grade, stage, or for death from prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Material and Methods {#ijc32233-sec-0002}
====================

Subjects and study design {#ijc32233-sec-0003}
-------------------------

EPIC includes 153,457 men recruited between 1992 and 2000 from 19 centers, most aged 35--70 years, in 19 centers in eight European countries (Denmark, Germany, Greece, Italy, Netherlands, Spain, Sweden and United Kingdom (UK)) (more details in Supporting Information Methods). The details of the study design used in the EPIC study have been described elsewhere.[13](#ijc32233-bib-0013){ref-type="ref"} Men were not eligible for this analysis if they were diagnosed with cancer (except nonmelanoma skin cancer) before recruitment (*n* = 3,972), if they had missing dates of prostate cancer diagnosis (*n* = 14) or follow‐up (*n* = 1,433), or if they were aged \<20 years at recruitment (*n* = 2). Men were also excluded if they had no nondietary or dietary data, or if they had an extreme energy intake in relation to estimated requirement (top and bottom 1%, *n* = 5,766).[14](#ijc32233-bib-0014){ref-type="ref"} Complete data on diet and follow‐up for prostate cancer were available for 142,239 men (Supporting Information Fig. S1).

Assessment of dietary intake and other predictor variables {#ijc32233-sec-0004}
----------------------------------------------------------

At baseline, information was collected on lifestyle, health status, socio‐demographic characteristics, anthropometry and medical history.[13](#ijc32233-bib-0013){ref-type="ref"} Dietary intake during the year before enrolment was measured by country‐ or center‐specific validated food frequency questionnaires (FFQs) or diet histories, as previously described.[13](#ijc32233-bib-0013){ref-type="ref"}, [15](#ijc32233-bib-0015){ref-type="ref"} To correct for any systematic under‐ or overestimation of dietary intake across the participating centers, dietary intakes from the questionnaires were calibrated using a standardized, computer‐based, 24‐h dietary recall method in an 8% random sample of the whole EPIC cohort.

In order to estimate the intakes of individual fatty acids, the EPIC Nutrient Database (ENDB) was matched with the National Nutrient Database for Standard Reference of the United States (NNDSR; developed at the USDA).[15](#ijc32233-bib-0015){ref-type="ref"}, [16](#ijc32233-bib-0016){ref-type="ref"} The fatty acid intakes reported in this manuscript were obtained through this extra USDA matching (more details in Supporting Information Methods). Due to the very small amounts of some individual fatty acids, we only included those with a mean total intake of at least 0.05 g/day in these analyses, with the exception of docosapentaenoic acid (22:5n‐3c), which was included due to its previously suggested role in prostate cancer risk.[12](#ijc32233-bib-0012){ref-type="ref"} Fatty acids were presented and analyzed as grams per 1,000 kcal/day in order to control for confounding by total energy intake.[17](#ijc32233-bib-0017){ref-type="ref"} Short chain fatty acids were strongly correlated with each other (Supporting Information Table S2A), probably because of their shared food sources[18](#ijc32233-bib-0018){ref-type="ref"}; therefore, in addition to analyzing short chain SFAs individually, they were also combined together in groups as 4:0--10:0 and 12:0--14:0.[10](#ijc32233-bib-0010){ref-type="ref"}

Ascertainment of prostate cancer {#ijc32233-sec-0005}
--------------------------------

The main source of information on cancer incidence, tumor subtypes and vital status was population‐based cancer and mortality registries. In Germany and Greece follow‐up was based on a combination of methods, including health insurance records, cancer and pathology registries, as well as active follow‐up through participants or relatives; self‐reported incident cancers were verified through medical records. Follow‐up began at the date of recruitment and was censored at the date of last known contact, or at the date of diagnosis of cancer, death, emigration or the end of the follow‐up period, whichever came first. Prostate cancer (*n* = 7,036) was defined as code C61 in the 10th Revision of the International Statistical Classification of Diseases, Injuries and Causes of Death (ICD).[19](#ijc32233-bib-0019){ref-type="ref"}

Grade (based on Gleason sum) was classified as low‐intermediate (Gleason sum of \<8, or grade coded as well, moderately, or poorly differentiated; *n* = 3,757) or high (Gleason sum of ≥8, or grade coded as undifferentiated; *n* = 726) grade. Information on stage was based on tumor‐node‐metastasis (TNM) staging code. Localized stage included those confined within the prostate and with no metastases at diagnosis (TNM staging score of ≤T~2~ and N~0~/N~x~ and M~0~, or stage coded in the recruitment center as localized; *n* = 2,641). Advanced cases included tumors that had spread beyond the prostate at diagnosis (T~3~‐T~4~ and/or N~1~‐N~3~ and/or M~1~, and/or stage coded in the recruitment center as metastatic; *n* = 1,389). Fatal cases were those who died of prostate cancer (*n* = 936).

Statistical analysis {#ijc32233-sec-0006}
--------------------

Baseline characteristics of the study population were calculated across fifths of total SFAs, MUFAs and PUFAs intake in grams/1000 kcal and presented as means with standard deviations (SDs) for continuous variables or percentages for categorical variables. Pearson correlations between intakes of individual SFAs, MUFAs and PUFAs were calculated.

Each individual fatty acid was divided into fifths of intake in grams/1000 kcal/day based on the distribution in the EPIC cohort and also modeled as continuous variables per SD higher intake.

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models using attained age as the underlying time variable. The date of last follow‐up ranged from January 2011 in Germany to October 2013 in Spain. All analyses were stratified by center and age (\<50, 50--54.9, 55--59.9, 60--64.9, 65--69.9, and ≥70 years) at recruitment. To check for violation of the proportional hazards assumption we used time‐varying covariates and Schoenfeld residuals, which did not indicate violation from the proportional hazards assumption. Tests for linear trend were performed using continuous values for dietary fatty acids, with increments based on one SD increase. All models were adjusted for educational level (no degree or equivalent, degree or equivalent, unknown), smoking status (never, former, current, unknown), marital status (married or cohabiting, not married or cohabiting, unknown), diabetes (no, yes, unknown), physical activity (inactive, moderately inactive, moderately active, active, unknown[20](#ijc32233-bib-0020){ref-type="ref"}), height (\<170, 170--174, 175--179, ≥180 cm, unknown), BMI (\<22.5, 22.5--24.9, 25--29.9, ≥30 kg/m^2^, unknown), and total energy intake (fifths). Participants with missing values were assigned an "unknown" category; \<3% of values were missing for each covariate, with the exception of marital status, for which 30% of values were missing.

Tests for heterogeneity of trends for histological grade (low‐intermediate or high), tumor stage (localized or advanced), and time between blood collection and diagnosis (\<5 years, ≥5 years)\] were performed. For this, we fitted separate models for each subgroup assuming independence of the HRs using a method analogous to competing risks, and compared the risk coefficients and standard errors in the subgroups of interest after excluding cases of unknown grade or stage.[21](#ijc32233-bib-0021){ref-type="ref"}

All analyses were performed using Stata version 14.1 (Stata Corporation, College Station, TX), all tests of significance were two‐sided, and a *p*‐value less than 0.05 was considered statistically significant. Conventional *p*‐values are shown but the results were interpreted in the light of the number of tests performed.

Results {#ijc32233-sec-0007}
=======

A total of 7,036 men were diagnosed with prostate cancer after an average follow‐up time of 13.9 years. The median age at prostate cancer diagnosis was 68 years (range, 41--95 years). Table [1](#ijc32233-tbl-0001){ref-type="table"} shows the characteristics of the study participants at baseline. Some baseline characteristics varied by fatty acids consumption. For example, men in the highest fifth of SFAs intake were more likely to have an education degree and have a higher total energy intake. Men in the highest fifths of MUFAs and PUFAs intake were more likely to be younger at recruitment and older at prostate cancer diagnosis.

###### 

Baseline characteristics of 142,239 men in EPIC (1992--2013) according to observed SFAs, MUFAs and PUFAs intakes

                                                                       Fifths of observed SFAs intake   Fifths of observed MUFAs intake   Fifths of observed PUFAs intake                                                                                   
  -------------------------------------------------------------------- -------------------------------- --------------------------------- --------------------------------- --------------- --------------- --------------- --------------- --------------- ---------------
  No. of men                                                           28,448                           28,448                            28,447                            28,448          28,448          28,447          28,448          28,448          28,447
  Age at recruitment[1](#ijc32233-note-0004){ref-type="fn"}, y         52.2 (9.7)                       51.7 (10.3)                       51.1 (10.3)                       52.8 (10.6)     51.8 (9.8)      50.6 (10.5)     52.3 (8.5)      51.7 (10.1)     51.0 (11.4)
  Age at diagnosis[1](#ijc32233-note-0004){ref-type="fn"}, y           67.8 (6.4)                       68.1 (6.8)                        67.5 (6.9)                        68.7 (6.8)      68.0 (6.5)      66.9 (6.7)      67.1 (6.2)      67.8 (6.6)      68.5 (7.0)
  *Smoking, n (%)*                                                                                                                                                                                                                                          
  Never                                                                8,990 (31.6)                     9,475 (33.3)                      9,526 (33.5)                      9,958 (35.0)    9,713 (34.1)    8,175 (28.7)    7,794 (27.4)    9,721 (34.2)    10,262 (36.1)
  Former                                                               10,650 (37.4)                    10,266 (36.1)                     9,838 (34.6)                      11,130 (39.1)   10,299 (36.2)   9,400 (33.0)    10,983 (38.6)   10,481 (36.8)   9,347 (32.9)
  Current                                                              8,479 (29.8)                     8,281 (29.1)                      8,704 (30.6)                      6,979 (24.5)    8,137 (28.6)    10,193 (35.8)   9,375 (33.0)    7,892 (27.7)    8,324 (29.3)
  *Educational level, n (%)*                                                                                                                                                                                                                                
  No degree                                                            20,722 (72.8)                    20,560 (72.3)                     18,919 (66.5)                     18,064 (63.5)   19,806 (69.6)   22,702 (79.8)   21,226 (74.6)   19,770 (69.5)   19,954 (70.1)
  Degree                                                               6,638 (23.3)                     7,156 (25.2)                      8,918 (31.3)                      8,724 (30.7)    7,996 (28.1)    5,552 (19.5)    6,887 (24.2)    8,014 (28.2)    7,139 (25.1)
  *Physical activity, n (%)*                                                                                                                                                                                                                                
  Inactive                                                             5,527 (19.4)                     5,134 (18.0)                      5,539 (19.5)                      5,366 (18.9)    4,745 (16.7)    6,816 (24.0)    5,002 (17.6)    5,221 (18.4)    5,861 (20.6)
  Moderately inactive                                                  8,502 (29.9)                     8,721 (30.7)                      8,854 (31.1)                      8,426 (29.6)    8,770 (30.8)    8,782 (30.9)    9,033 (31.8)    8,618 (30.3)    8,285 (29.1)
  Moderately active                                                    6,950 (24.4)                     6,793 (23.9)                      6,958 (24.5)                      6,773 (23.8)    6,906 (24.3)    7,013 (24.7)    6,943 (24.4)    7,004 (24.6)    6,992 (24.6)
  Active                                                               7,190 (25.3)                     7,088 (24.9)                      6,320 (22.2)                      7,297 (25.7)    7,271 (25.6)    5,570 (19.6)    7,272 (25.6)    6,870 (24.1)    6,516 (22.9)
  *Diabetes at baseline, n (%)*                                                                                                                                                                                                                             
  No                                                                   26,578 (93.4)                    26,848 (94.4)                     26,869 (94.5)                     26,618 (93.6)   26,937 (94.7)   26,610 (93.5)   27,048 (95.1)   26,715 (93.9)   26,680 (93.8)
  Yes                                                                  1,203 (4.2)                      923 (3.2)                         1,064 (3.7)                       1,024 (3.6)     864 (3.0)       1,459 (5.1)     981 (3.4)       1,104 (3.9)     961 (3.4)
  *Marital status, n (%)*                                                                                                                                                                                                                                   
  Married                                                              11,222 (39.4)                    16,441 (57.8)                     19,193 (67.5)                     14,234 (50.0)   15,587 (54.8)   18,378 (64.6)   16,023 (56.3)   15,925 (56.0)   15,389 (54.1)
  Not married                                                          2,944 (10.3)                     3,624 (12.7)                      4,983 (17.5)                      4,210 (14.8)    3,707 (13.0)    3,117 (11.0)    3,084 (10.8)    3,785 (13.3)    4,395 (15.4)
  Height[1](#ijc32233-note-0004){ref-type="fn"}, cm                    173.1 (7.4)                      175.0 (7.3)                       175.8 (7.1)                       175.4 (7.0)     175.5 (7.2)     172.2 (7.5)     173.5 (7.3)     175.2 (7.2)     174.9 (7.5)
  BMI[1](#ijc32233-note-0004){ref-type="fn"}, kg/m^2^                  26.8 (3.7)                       26.4 (3.6)                        26.3 (3.7)                        26.3 (3.7)      26.2 (3.5)      27.3 (3.8)      26.7 (3.6)      26.5 (3.6)      26.2 (3.8)
  Total energy intake[1](#ijc32233-note-0004){ref-type="fn"}, Kcal/d   2,289 (641)                      2,426 (650)                       2,508 (701)                       2,232 (623)     2,442 (641)     2,500 (703)     2,431 (679)     2,391 (648)     2,438 (676)

Percentages do not match due to missing data. Fifths calculated from g/1000 kcal of each fatty acid.

Values are means (SD).

Abbreviations: BMI, body mass index; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids.

Palmitic acid (16:0), oleic acid (18:1n‐9c) and linoleic acid (18:2n‐6c) were the largest contributors to total SFAs, MUFAs and PUFAs intake, respectively (Supporting Information Table S1). Butyric acid (4:0), caproic acid (6:0), caprylic acid (8:0) and capric acid (10:0) were strongly correlated with each other (correlation coefficients ranged from 0.840 to 0.972). There was also a strong correlation between palmitic acid (16:0) and stearic acid (18:0) (correlation coefficient 0.814, Supporting Information Table S2A). Although individual MUFAs were correlated, these correlations were not very strong (Supporting Information Table S2B). The PUFAs eicosapentaenoic acid (20:5n‐3c), docosapentaenoic acid (22:5n‐3c) and docosahexaenoic acid (22:6n‐3c) were also strongly correlated (correlation coefficients ranged from 0.872 to 0.968, Supporting Information Table S2C).

The associations of intakes of individual SFAs, MUFAs and PUFAs with risk for overall prostate cancer, prostate cancer subdivided by grade and stage of disease, and for prostate cancer death, using both the observed and calibrated intakes, are shown in Tables [2](#ijc32233-tbl-0002){ref-type="table"} (Supporting Information Table S3 for observed intakes), [3](#ijc32233-tbl-0003){ref-type="table"} (Supporting Information Table S4 for observed intakes), and [4](#ijc32233-tbl-0004){ref-type="table"} (Supporting Information Table S5 for observed intakes), respectively. Results for observed and calibrated intakes were similar in direction; therefore, from here on we will only report calibrated results.

###### 

Multivariable‐adjusted hazard ratios (95% CI) for prostate cancer per 1‐SD increase of total fat and individual saturated fatty acids intake in 142,239 men in EPIC (1992--2013)

                                            Calibrated              
  ----------------------------- ------- ------------------- ------- -------
  *Total Fat*                                                       
  Total prostate cancer          7,036   0.99 (0.96--1.02)   0.389  
  Grade                                                             
  Low                            3,757   0.95 (0.91--1.00)   0.038  
  High                            726    1.04 (0.95--1.14)   0.419  0.084
  Stage                                                             
  Localized                      2,641   0.98 (0.93--1.04)   0.544  
  Advanced                       1,389   1.01 (0.95--1.08)   0.708  0.392
  Fatal prostate cancer           936    1.00 (0.92--1.08)   0.965  
  *Total SFAs*                                                      
  Total prostate cancer          7,036   1.00 (0.96--1.03)   0.850  
  Grade                                                             
  Low                            3,757   0.96 (0.92--1.01)   0.144  
  High                            726    1.07 (0.96--1.19)   0.234  0.041
  Stage                                                             
  Localized                      2,641   0.97 (0.91--1.02)   0.239  
  Advanced                       1,389   1.05 (0.97--1.13)   0.257  0.052
  Fatal prostate cancer           936    1.02 (0.92--1.12)   0.723  
  *Butyric acid (4:0)*                                              
  Total prostate cancer          7,036   1.01 (0.98--1.04)   0.496  
  Grade                                                             
  Low                            3,757   0.99 (0.95--1.03)   0.724  
  High                            726    1.07 (0.97--1.17)   0.162  0.035
  Stage                                                             
  Localized                      2,641   0.96 (0.92--1.01)   0.135  
  Advanced                       1,389   1.08 (1.01--1.15)   0.026  0.004
  Fatal prostate cancer           936    1.02 (0.94--1.12)   0.599  
  *Caproic acid (6:0)*                                              
  Total prostate cancer          7,036   1.00 (0.97--1.04)   0.819  
  Grade                                                             
  Low                            3,757   0.98 (0.94--1.02)   0.380  
  High                            726    1.06 (0.97--1.16)   0.198  0.034
  Stage                                                             
  Localized                      2,641   0.96 (0.91--1.00)   0.071  
  Advanced                       1,389   1.06 (1.00--1.13)   0.053  0.006
  Fatal prostate cancer           936    1.03 (0.95--1.12)   0.476  
  *Caprylic acid (8:0)*                                             
  Total prostate cancer          7,036   1.00 (0.97--1.03)   0.937  
  Grade                                                             
  Low                            3,757   0.97 (0.93--1.01)   0.156  
  High                            726    1.04 (0.95--1.14)   0.394  0.068
  Stage                                                             
  Localized                      2,641   0.95 (0.91--1.00)   0.042  
  Advanced                       1,389   1.05 (0.99--1.12)   0.122  0.013
  Fatal prostate cancer           936    1.05 (0.97--1.13)   0.272  
  *Capric acid (10:0)*                                              
  Total prostate cancer          7,036   1.01 (0.97--1.04)   0.775  
  Grade                                                             
  Low                            3,757   0.98 (0.94--1.03)   0.397  
  High                            726    1.06 (0.95--1.17)   0.317  0.072
  Stage                                                             
  Localized                      2,641   0.96 (0.90--1.01)   0.116  
  Advanced                       1,389   1.06 (0.99--1.14)   0.093  0.023
  Fatal prostate cancer           936    1.04 (0.94--1.14)   0.481  
  *Lauric acid (12:0)*                                              
  Total prostate cancer          7,036   1.00 (0.97--1.04)   0.791  
  Grade                                                             
  Low                            3,757   0.98 (0.93--1.02)   0.333  
  High                            726    1.07 (0.97--1.19)   0.182  0.102
  Stage                                                             
  Localized                      2,641   0.96 (0.91--1.01)   0.153  
  Advanced                       1,389   1.07 (0.99--1.14)   0.079  0.078
  Fatal prostate cancer           936    1.06 (0.96--1.17)   0.253  
  *Myristic acid (14:0)*                                            
  Total prostate cancer          7,036   1.00 (0.97--1.04)   0.916  
  Grade                                                             
  Low                            3,757   0.97 (0.93--1.02)   0.208  
  High                            726    1.06 (0.96--1.17)   0.265  0.028
  Stage                                                             
  Localized                      2,641   0.96 (0.91--1.01)   0.113  
  Advanced                       1,389   1.06 (0.98--1.14)   0.129  0.013
  Fatal prostate cancer           936    1.04 (0.95--1.14)   0.426  
  *Pentadecanoic acid (15:0)*                                       
  Total prostate cancer          7,036   0.98 (0.94--1.01)   0.152  
  Grade                                                             
  Low                            3,757   0.99 (0.94--1.04)   0.618  
  High                            726    0.93 (0.84--1.03)   0.146  0.427
  Stage                                                             
  Localized                      2,641   0.96 (0.91--1.02)   0.212  
  Advanced                       1,389   0.97 (0.91--1.04)   0.430  0.511
  Fatal prostate cancer           936    0.97 (0.89--1.05)   0.410  
  *Palmitic acid (16:0)*                                            
  Total prostate cancer          7,036   0.99 (0.95--1.03)   0.627  
  Grade                                                             
  Low                            3,757   0.96 (0.91--1.01)   0.104  
  High                            726    1.06 (0.95--1.19)   0.282  0.064
  Stage                                                             
  Localized                      2,641   0.97 (0.91--1.03)   0.324  
  Advanced                       1,389   1.03 (0.95--1.12)   0.436  0.131
  Fatal prostate cancer           936    1.02 (0.92--1.12)   0.709  
  *Margaric acid (17:0)*                                            
  Total prostate cancer          7,036   0.99 (0.96--1.02)   0.549  
  Grade                                                             
  Low                            3,757   0.98 (0.94--1.03)   0.442  
  High                            726    1.03 (0.93--1.13)   0.562  0.130
  Stage                                                             
  Localized                      2,641   0.96 (0.92--1.01)   0.141  
  Advanced                       1,389   1.06 (0.99--1.13)   0.099  0.036
  Fatal prostate cancer           936    0.98 (0.90--1.08)   0.738  
  *Stearic acid (18:0)*                                             
  Total prostate cancer          7,036   0.99 (0.95--1.03)   0.628  
  Grade                                                             
  Low                            3,757   0.96 (0.90--1.01)   0.118  
  High                            726    1.06 (0.94--1.20)   0.349  0.087
  Stage                                                             
  Localized                      2,641   0.97 (0.90--1.04)   0.357  
  Advanced                       1,389   1.04 (0.95--1.14)   0.387  0.117
  Fatal prostate cancer           936    0.99 (0.89--1.10)   0.799  
  *Arachidic acid (20:0)*                                           
  Total prostate cancer          7,036   0.99 (0.94--1.04)   0.801  
  Grade                                                             
  Low                            3,757   0.99 (0.93--1.06)   0.861  
  High                            726    0.95 (0.81--1.12)   0.565  0.963
  Stage                                                             
  Localized                      2,641   1.01 (0.94--1.10)   0.739  
  Advanced                       1,389   0.96 (0.86--1.07)   0.458  0.297
  Fatal prostate cancer           936    0.89 (0.77--1.04)   0.140  
  *Behenic acid (22:0)*                                             
  Total prostate cancer          7,036   0.99 (0.95--1.03)   0.616  
  Grade                                                             
  Low                            3,757   0.99 (0.94--1.04)   0.707  
  High                            726    0.90 (0.76--1.06)   0.210  0.665
  Stage                                                             
  Localized                      2,641   1.02 (0.95--1.09)   0.581  
  Advanced                       1,389   0.94 (0.85--1.04)   0.243  0.275
  Fatal prostate cancer           936    0.90 (0.77--1.04)   0.156  
  *4:0--10:0*                                                       
  Total prostate cancer          7,036   1.01 (0.97--1.04)   0.718  
  Grade                                                             
  Low                            3,757   0.98 (0.94--1.03)   0.435  
  High                            726    1.06 (0.96--1.16)   0.234  0.043
  Stage                                                             
  Localized                      2,641   0.96 (0.91--1.01)   0.093  
  Advanced                       1,389   1.07 (1.00--1.14)   0.054  0.008
  Fatal prostate cancer           936    1.03 (0.95--1.12)   0.464  
  *12:0--14:0*                                                      
  Total prostate cancer          7,036   1.00 (0.97--1.04)   0.859  
  Grade                                                             
  Low                            3,757   0.97 (0.93--1.02)   0.229  
  High                            726    1.07 (0.96--1.18)   0.223  0.030
  Stage                                                             
  Localized                      2,641   0.96 (0.91--1.01)   0.124  
  Advanced                       1,389   1.06 (0.99--1.14)   0.103  0.016
  Fatal prostate cancer           936    1.05 (0.96--1.16)   0.299  

Cox regression analysis. All models are stratified by centre and age at recruitment and adjusted for age (underlying time variable), educational level (no degree, degree or unknown), smoking status (never, former, current or unknown), marital status (married, not married, unknown), diabetes (yes, no, unknown), physical activity (inactive, moderately inactive, moderately active, active, unknown), height (\<170, 170--174, 175--179, ≥180 cm or unknown), body mass index (\<22.5, 22.5--24.9, 25--29.9, ≥30 kg/m[2](#ijc32233-note-0009){ref-type="fn"} or unknown), and total energy intake (fifths).

Low‐intermediate grade (Gleason score of \<8, or grade coded as well, moderately, or poorly differentiated). High grade (Gleason score of ≥8, or grade coded as undifferentiated). Localized stage (TNM staging score of T0‐T2 and N0/Nx and M0, or stage coded in the recruitment centre as localized). Advanced stage (T3‐T4 and/or N1‐N3 and/or M1, and/or stage coded in the recruitment centre as metastatic).

HR (95% CI) estimated per 1‐SD increase in fatty acids intake.

Linear trends for HRs estimates over a continuous scale of the individual fatty acid.

*P*‐value from test for heterogeneity for the associations of intake the individual fatty acids with risk of prostate cancer categorized according to prostate tumor grade (low‐intermediate or high) and stage (localized or advanced).

Abbreviation: SFAs saturated fatty acids.

###### 

Multivariable‐adjusted hazard ratios (95% CI) for prostate cancer per 1‐SD increase of individual monounsaturated fatty acids intake in 142,239 men in EPIC (1992--2013)

                                              Calibrated              
  ------------------------------- ------- ------------------- ------- -------
  *Total MUFAs*                                                       
  Total prostate cancer            7,036   0.98 (0.93--1.02)   0.303  
  Grade                                                               
  Low                              3,757   0.95 (0.90--1.01)   0.121  
  High                              726    1.04 (0.91--1.18)   0.613  0.411
  Stage                                                               
  Localized                        2,641   1.00 (0.93--1.08)   0.991  
  Advanced                         1,389   1.01 (0.91--1.11)   0.920  0.942
  Fatal prostate cancer             936    0.98 (0.87--1.10)   0.676  
  *Palmitoleic acid (16:1n‐7c)*                                       
  Total prostate cancer            7,036   1.00 (0.94--1.05)   0.893  
  Grade                                                               
  Low                              3,757   0.96 (0.89--1.04)   0.353  
  High                              726    1.08 (0.91--1.28)   0.372  0.317
  Stage                                                               
  Localized                        2,641   1.01 (0.92--1.11)   0.779  
  Advanced                         1,389   1.02 (0.91--1.15)   0.742  0.731
  Fatal prostate cancer             936    1.06 (0.91--1.23)   0.446  
  *Oleic acid (18:1n‐9c)*                                             
  Total prostate cancer            7,036   0.98 (0.94--1.03)   0.405  
  Grade                                                               
  Low                              3,757   0.96 (0.90--1.02)   0.182  
  High                              726    1.03 (0.89--1.18)   0.686  0.517
  Stage                                                               
  Localized                        2,641   0.99 (0.92--1.07)   0.847  
  Advanced                         1,389   1.02 (0.92--1.13)   0.777  0.945
  Fatal prostate cancer             936    0.98 (0.87--1.11)   0.744  
  *Eicosenoic acid (20:1n‐9c)*                                        
  Total prostate cancer            7,036   1.01 (0.98--1.03)   0.540  
  Grade                                                               
  Low                              3,757   0.98 (0.94--1.02)   0.283  
  High                              726    1.05 (0.99--1.12)   0.094  0.174
  Stage                                                               
  Localized                        2,641   1.00 (0.95--1.04)   0.932  
  Advanced                         1,389   1.02 (0.97--1.06)   0.512  0.550
  Fatal prostate cancer             936    1.05 (1.00--1.11)   0.048  
  *Erucic acid (22:1n‐9c)*                                            
  Total prostate cancer            7,036   1.01 (0.98--1.03)   0.500  
  Grade                                                               
  Low                              3,757   0.97 (0.93--1.02)   0.262  
  High                              726    1.06 (0.99--1.12)   0.091  0.129
  Stage                                                               
  Localized                        2,641   1.00 (0.95--1.04)   0.865  
  Advanced                         1,389   1.02 (0.98--1.07)   0.363  0.313
  Fatal prostate cancer             936    1.05 (1.00--1.11)   0.055  

Cox regression analysis. All models are stratified by centre and age at recruitment and adjusted for age (underlying time variable), educational level (no degree, degree or unknown), smoking status (never, former, current or unknown), marital status (married, not married, unknown), diabetes (yes, no, unknown), physical activity (inactive, moderately inactive, moderately active, active, unknown), height (\<170, 170--174, 175--179, ≥180 cm or unknown), body mass index (\<22.5, 22.5--24.9, 25--29.9, ≥30 kg/m[2](#ijc32233-note-0015){ref-type="fn"} or unknown), and total energy intake (fifths).

Low‐intermediate grade (Gleason score of \<8, or grade coded as well, moderately, or poorly differentiated). High grade (Gleason score of ≥8, or grade coded as undifferentiated). Localized stage (TNM staging score of T0‐T2 and N0/Nx and M0, or stage coded in the recruitment centre as localized). Advanced stage (T3‐T4 and/or N1‐N3 and/or M1, and/or stage coded in the recruitment centre as metastatic).

HR (95% CI) estimated per 1‐SD increase in fatty acids intake.

Linear trends for HRs estimates over a continuous scale of the individual fatty acid.

*p*‐value from test for heterogeneity for the associations of intake the individual fatty acids with risk of prostate cancer categorized according to prostate tumor grade (low‐intermediate or high) and stage (localized or advanced).

Abbreviations: MUFAs, monounsaturated fatty acids.

###### 

Multivariable‐adjusted hazard ratios (95% CI) for prostate cancer per 1‐SD increase of individual polyunsaturated fatty acids intake in 142,239 men in EPIC (1992--2013)

                                                   Calibrated              
  ------------------------------------ ------- ------------------- ------- -------
  *Total PUFAs*                                                            
  Total prostate cancer                 7,036   0.98 (0.95--1.02)   0.340  
  Grade                                                                    
  Low                                   3,757   0.96 (0.91--1.01)   0.086  
  High                                   726    1.00 (0.91--1.11)   0.925  0.508
  Stage                                                                    
  Localized                             2,641   0.99 (0.94--1.05)   0.830  
  Advanced                              1,389   0.97 (0.90--1.05)   0.434  0.777
  Fatal prostate cancer                  936    0.99 (0.90--1.09)   0.836  
  *Linoleic acid (18:2n‐6c)*                                               
  Total prostate cancer                 7,036   0.98 (0.95--1.02)   0.311  
  Grade                                                                    
  Low                                   3,757   0.96 (0.91--1.00)   0.063  
  High                                   726    1.01 (0.91--1.12)   0.857  0.450
  Stage                                                                    
  Localized                             2,641   0.99 (0.93--1.05)   0.678  
  Advanced                              1,389   0.97 (0.90--1.05)   0.440  0.824
  Fatal prostate cancer                  936    0.99 (0.90--1.08)   0.822  
  *α‐Linolenic acid (18:3n‐3c)*                                            
  Total prostate cancer                 7,036   0.99 (0.95--1.02)   0.502  
  Grade                                                                    
  Low                                   3,757   0.97 (0.92--1.02)   0.270  
  High                                   726    1.01 (0.91--1.13)   0.817  0.514
  Stage                                                                    
  Localized                             2,641   0.98 (0.92--1.05)   0.602  
  Advanced                              1,389   1.00 (0.93--1.08)   0.907  0.434
  Fatal prostate cancer                  936    0.99 (0.90--1.09)   0.839  
  *Arachidonic acid (20:4n‐6c)*                                            
  Total prostate cancer                 7,036   0.99 (0.95--1.03)   0.638  
  Grade                                                                    
  Low                                   3,757   0.97 (0.92--1.03)   0.387  
  High                                   726    0.94 (0.82--1.08)   0.381  0.404
  Stage                                                                    
  Localized                             2,641   1.05 (0.97--1.13)   0.213  
  Advanced                              1,389   0.91 (0.82--1.01)   0.072  0.021
  Fatal prostate cancer                  936    1.03 (0.92--1.15)   0.636  
  *Eicosapentaenoic acid (20:5n‐3c)*                                       
  Total prostate cancer                 7,036   1.02 (0.99--1.04)   0.272  
  Grade                                                                    
  Low                                   3,757   1.01 (0.96--1.05)   0.762  
  High                                   726    0.99 (0.92--1.08)   0.895  0.660
  Stage                                                                    
  Localized                             2,641   1.02 (0.98--1.07)   0.343  
  Advanced                              1,389   1.01 (0.95--1.07)   0.831  0.601
  Fatal prostate cancer                  936    1.07 (1.00--1.14)   0.045  
  *Docosapentaenoic acid (22:5n‐3c)*                                       
  Total prostate cancer                 7,036   1.00 (0.97--1.03)   0.989  
  Grade                                                                    
  Low                                   3,757   1.00 (0.96--1.04)   0.809  
  High                                   726    0.97 (0.90--1.05)   0.454  0.357
  Stage                                                                    
  Localized                             2,641   1.03 (0.98--1.08)   0.251  
  Advanced                              1,389   1.00 (0.94--1.06)   0.914  0.229
  Fatal prostate cancer                  936    1.03 (0.97--1.10)   0.325  
  *Docosahexaenoic acid (22:6n‐3c)*                                        
  Total prostate cancer                 7,036   1.01 (0.98--1.04)   0.504  
  Grade                                                                    
  Low                                   3,757   1.00 (0.96--1.05)   0.875  
  High                                   726    0.97 (0.89--1.06)   0.523  0.388
  Stage                                                                    
  Localized                             2,641   1.02 (0.97--1.07)   0.504  
  Advanced                              1,389   1.00 (0.94--1.07)   0.884  0.479
  Fatal prostate cancer                  936    1.06 (0.99--1.14)   0.083  

Cox regression analysis. All models are stratified by centre and age at recruitment and adjusted for age (underlying time variable), educational level (no degree, degree or unknown), smoking status (never, former, current or unknown), marital status (married, not married, unknown), diabetes (yes, no, unknown), physical activity (inactive, moderately inactive, moderately active, active, unknown), height (\<170, 170--174, 175--179, ≥180 cm or unknown), body mass index (\<22.5, 22.5--24.9, 25--29.9, ≥30 kg/m[2](#ijc32233-note-0021){ref-type="fn"} or unknown), and total energy intake (fifths).

Low‐intermediate grade (Gleason score of \<8, or grade coded as well, moderately, or poorly differentiated). High grade (Gleason score of ≥8, or grade coded as undifferentiated). Localized stage (TNM staging score of T0‐T2 and N0/Nx and M0, or stage coded in the recruitment centre as localized). Advanced stage (T3‐T4 and/or N1‐N3 and/or M1, and/or stage coded in the recruitment centre as metastatic).

HR (95% CI) estimated per 1‐SD increase in fatty acids intake.

Linear trends for HRs estimates over a continuous scale of the individual fatty acid.

*P*‐value from test for heterogeneity for the associations of intake the individual fatty acids with risk of prostate cancer categorized according to prostate tumor grade (low‐intermediate or high) and stage (localized or advanced).

Abbreviation: PUFAs, polyunsaturated fatty acids.

Intakes of individual SFAs, MUFAs and PUFAs were not related to overall prostate cancer risk (Supporting Information Table S6 and Tables [2](#ijc32233-tbl-0002){ref-type="table"}, [3](#ijc32233-tbl-0003){ref-type="table"} and [4](#ijc32233-tbl-0004){ref-type="table"}). Removing BMI as a covariate in the model has no impact on any of the results. There was no evidence of heterogeneity in separate analyses by grade (Tables [2](#ijc32233-tbl-0002){ref-type="table"}, [3](#ijc32233-tbl-0003){ref-type="table"} and [4](#ijc32233-tbl-0004){ref-type="table"} **)**. We found evidence of heterogeneity in the association of some SFAs \[butyric acid (4:0), caproic acid (6:0), 4:0--10:0 combined and 12:0--14:0 combined\] with prostate cancer risk by tumor stage (*p* ~heterogeneity for\ all~ \< 0.03; Table [2](#ijc32233-tbl-0002){ref-type="table"}), with a positive association with risk of advanced stage disease for butyric acid (4:0; HR~1SD\ in\ calibrated\ intake~ = 1.08; 1.01--1.15; *p*‐trend = 0.026), and no significant associations with localized disease. There was also evidence of heterogeneity by tumor stage (*p* ~heterogeneity~ = 0.021) in the association between arachidonic acid (20:4n‐6c) with prostate cancer risk, with a higher intake of this PUFA being weakly associated with a lower risk of advanced disease (HR~1SD\ in\ calibrated\ intake~ = 0.91, 0.82--1.01; *p*‐trend = 0.072; Table [4](#ijc32233-tbl-0004){ref-type="table"}).

We observed no associations between intakes of individual dietary fatty acids and prostate cancer death, with the exception of a small increased risk for those with a higher intake of eicosenoic acid (22:1n‐9c; HR~1SD\ in\ calibrated\ intake~ = 1.05; 95% CI 1.00--1.11; *p*‐trend = 0.048; Table [3](#ijc32233-tbl-0003){ref-type="table"}) and eicosapentaenoic acid (20:5n‐3c; HR~1SD\ in\ calibrated\ intake~ = 1.07; 95% CI 1.00--1.14; *p*‐trend = 0.045; Table [4](#ijc32233-tbl-0004){ref-type="table"}).

Although there was some evidence of heterogeneity for the association of some long‐chain SFAs with total prostate cancer risk when subdivided by time between recruitment and diagnosis (\<5 years, ≥5 years; Supporting Information Table S7), the associations at each of the follow‐up times were not statistically significant. There was no evidence of heterogeneity for the rest of individual fatty acids by follow‐up time.

Discussion {#ijc32233-sec-0008}
==========

In this large prospective study, intakes of individual fatty acids were not associated with overall prostate cancer risk. However, a higher intake of butyric acid was positively associated with risk for advanced stage prostate cancer. There was also a small increased risk of fatal prostate cancer risk with higher intakes of eicosenoic acid and eicosapentaenoic acid.

The possible association between fat intake (total fat and specific fatty acids) with prostate cancer risk and/or progression has generated considerable debate. Animal and cell studies have shown that dietary fat can promote metastasis.[22](#ijc32233-bib-0022){ref-type="ref"}, [23](#ijc32233-bib-0023){ref-type="ref"}, [24](#ijc32233-bib-0024){ref-type="ref"} Several mechanisms that may underpin this association have been proposed. These include a positive association of total fat intake with IGF‐I[25](#ijc32233-bib-0025){ref-type="ref"} and androgen[26](#ijc32233-bib-0026){ref-type="ref"} concentrations and, based on experiments in mice, a possible role in the activation of the IGF‐Akt pathway and the proliferation of prostatic intraepithelial neoplasia (PIN) epithelial cells.[23](#ijc32233-bib-0023){ref-type="ref"} Nevertheless, data from prospective studies are inconclusive.[2](#ijc32233-bib-0002){ref-type="ref"} There are various differences between prospective studies that could account for the inconclusive findings, such as that most studies have combined grade and stage of the disease, and that the type of fatty acid rather than total amount may play a role in prostate cancer development and/or progression.

Our finding of an increased risk of advanced prostate cancer associated with higher butyric acid (4:0), caproic acid (6:0), and 4:0--10:0 combined intakes is difficult to put into context, as other prospective studies have not examined these associations. A previous survival analyses among Swedish men initially diagnosed with localized prostate cancer found that a higher intake of short chain fatty acids (4:0--10:0) may increase risk of prostate cancer death[27](#ijc32233-bib-0027){ref-type="ref"}; myristic acid (14:0) was also related with worse prostate cancer survival in this study, but we did not find an association of this SFA with prostate cancer risk. A prospective study in Japanese men also found a positive association between myristic and palmitic acid and prostate cancer risk.[28](#ijc32233-bib-0028){ref-type="ref"} Dairy products are the main dietary source of short chain fatty acids,[18](#ijc32233-bib-0018){ref-type="ref"} which might be involved in prostate cancer etiology.[2](#ijc32233-bib-0002){ref-type="ref"} Therefore, it is also possible that the observed associations are driven by other compounds present in dairy products, such as protein or calcium.[29](#ijc32233-bib-0029){ref-type="ref"} However, when we further adjusted the multivariable‐adjusted models for protein or calcium from dairy products, the significant association between butyric acid and advanced prostate cancer risk was maintained and was even a bit stronger (protein adjustment, HR~1SD\ in\ calibrated\ intake~ = 1.09; 1.02--1.16; *p*‐trend = 0.016; calcium adjustment, HR~1SD\ in\ calibrated\ intake~ = 1.09; 1.01--1.16; *p*‐trend = 0.020). Moreover, butter is particularly high in butyric acid and it is also a good source of phytanic acid, which has been related to prostate cancer in the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention Study,[30](#ijc32233-bib-0030){ref-type="ref"} a cohort of Finnish male smokers. Phytanic acid is also high in fish, and as discussed below, we have also found a weak association between eicosapentaenoic acid and death from prostate cancer. However, circulating phytanic acid concentrations were not significantly associated with prostate cancer risk in the EPIC cohort.[31](#ijc32233-bib-0031){ref-type="ref"}

A higher intake of arachidonic acid (20:4n‐6c) was weakly associated with a lower risk of advanced disease, which is consistent with a previous individual participant meta‐analysis of prospective studies on circulating fatty acids that found an inverse association with aggressive prostate cancer.[12](#ijc32233-bib-0012){ref-type="ref"} However, previous prospective studies have found no association between dietary arachidonic acid and prostate cancer risk.[32](#ijc32233-bib-0032){ref-type="ref"}, [33](#ijc32233-bib-0033){ref-type="ref"} The possible mechanisms whereby arachidonic acid may inhibit prostate cancer progression are unknown, because previous experimental studies have suggested that the arachidonic acid pathway may be implicated in prostate cancer development and progression through its involvement in inflammation and cell growth.[34](#ijc32233-bib-0034){ref-type="ref"} Further research is therefore needed before conclusions on risk can be drawn.

We also found some evidence that both eicosenoic (22:1n‐9c) and eicosapentaenoic acid (20:5n‐3c) may be associated with a higher risk of death from prostate cancer. To the best of our knowledge, no previous prospective study has looked at the association between eicosenoic acid and prostate cancer risk, but this fatty acid is often found in similar foods as eicosapentaenoic acid (e.g. fish, and nuts and seeds).[35](#ijc32233-bib-0035){ref-type="ref"} Circulating eicosapentaenoic acid concentrations have been associated with a higher risk of total prostate cancer in a pooled analysis of prospective studies[12](#ijc32233-bib-0012){ref-type="ref"} and dietary intake of eicosapentaenoic acid was associated with a higher risk of advanced and fatal prostate cancer in the NIH‐AARP study.[36](#ijc32233-bib-0036){ref-type="ref"} However, results from the Health Professionals Follow‐Up Study showed that a higher intake of eicosapentaenoic acid was associated with a lower risk of total and advanced prostate cancer.[32](#ijc32233-bib-0032){ref-type="ref"}

It was suggested in 1993 that α‐linolenic acid was positively associated with advanced prostate cancer.[37](#ijc32233-bib-0037){ref-type="ref"} However, our results, the latest meta‐analysis from the WCRF/AIRC,[2](#ijc32233-bib-0002){ref-type="ref"} and findings from a pooling study on circulating fatty acids[12](#ijc32233-bib-0012){ref-type="ref"} do not support the hypothesis that higher intake of α‐linolenic acid increases the risk of prostate cancer. Previous prospective studies have also suggested that docosapentaenoic acid (22:5n‐3c) is involved in prostate cancer development,[12](#ijc32233-bib-0012){ref-type="ref"} but we found no association between this fatty acid and prostate cancer risk. A Mendelian randomization analysis of data from up to 22,721 prostate cancer cases in the PRACTICAL consortia found no strong evidence for an association between several PUFAs, such as arachidonic acid, eicosapentaenoic acid, and docosapentaenoic acid, and overall and advanced prostate cancer risk.[38](#ijc32233-bib-0038){ref-type="ref"}

This study has some strengths and limitations that should be considered. The major strengths include the prospective design and the large sample size, which allowed investigation of fatty acids by stage and grade of prostate cancer tumors and death from prostate cancer. This study also had reliable identification of prostate cancer cases through cancer registries and/or verified medical records. The Gleason grade was based on data available from biopsies and surgical pathology, although there may be some misclassification because of changes in grading over time. The dietary questionnaires in all EPIC centers were validated and dietary intakes were calibrated using measures from a standardized 24‐h diet recall method to correct for over and under‐estimation of dietary intake.[15](#ijc32233-bib-0015){ref-type="ref"}

A limitation of the current study was the use of dietary fatty acids intake obtained from assessment questionnaires only at recruitment, which are subject to random measurement error and changes over time, and this would likely lead to an underestimation of true associations. Although we adjusted for multiple covariates, potential unmeasured and residual confounding cannot be excluded, including having a PSA test which was not available in our cohort. In addition, some of the associations observed might be due to chance because of the number of tests performed, and if we correct for multiple testing there would not be any significant results. Moreover, because some dietary fatty acids are highly correlated, it is difficult to disentangle their independent associations with prostate cancer. It is also unclear whether the risk differences observed in our study are attributable to the individual fatty acids or if they might be driven by other compound(s) in their food sources. Finally the fatty acids food sources may vary across the European countries included in this study, for example, the primary food that contributes to oleic acid intake in the south of Europe is olive oil, whereas in some populations in the north of Europe the primary food source is meat.[39](#ijc32233-bib-0039){ref-type="ref"}

In conclusion, intakes of individual fatty acids were not related to overall prostate cancer risk. However, our results suggest that higher intake of butyric acid may be associated with an increased risk of advanced prostate cancer. We also found a suggestive increased risk of fatal prostate cancer risk with higher intakes of eicosenoic acid and eicosapentaenoic acid. Further prospective studies and meta‐analyses are required to better understand the role of individual dietary fatty acids in prostate cancer development and progression.
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